Application of clinical judgment and guidelines to achieving glycemic goals in type 2 diabetes: focus on pharmacologic therapy (Q38219485)

31 August 2017

title

Application of clinical judgment and guidelines to achieving glycemic goals in type 2 diabetes: focus on pharmacologic therapy (English)

1 reference

31 August 2017

1 reference

Tamer G Yacoub

1

1 reference

31 August 2017

language of work or name

English

0 references

publication date

1 May 2014

1 reference

31 August 2017

published in

Postgraduate Medicine

1 reference

31 August 2017

volume

126

1 reference

31 August 2017

issue

3

1 reference

31 August 2017

page(s)

95-106

1 reference

Overview of the guidelines and evidence for the pharmacologic management of type 2 diabetes mellitus

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

Standards of medical care in diabetes--2014

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

AACE comprehensive diabetes management algorithm 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

Individualized treatment of type 2 diabetes mellitus using noninsulin agents: clinical considerations for the primary care physician

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

Group based diabetes self-management education compared to routine treatment for people with type 2 diabetes mellitus. A systematic review with meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

National trends in treatment of type 2 diabetes mellitus, 1994-2007

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

Novel pharmacological approaches to the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

Evidence based medicine: what it is and what it isn't

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

Failure of clinical practice guidelines to meet institute of medicine standards: Two more decades of little, if any, progress

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

A review and critical analysis of professional societies' guidelines for pharmacologic management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

Individualizing therapies in type 2 diabetes mellitus based on patient characteristics: what we know and what we need to know

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

Metabolic memory for vascular disease in diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

N of 1 trials in diabetes: making individual therapeutic decisions

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline From the American College of Physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

Potential drug interactions associated with treatments for type 2 diabetes and its comorbidities: a clinical pharmacology review

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

Baseline differences in A1C explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

Baseline HbA1c predicts attainment of 7.0% HbA1c target with structured titration of insulin glargine in type 2 diabetes: a patient-level analysis of 12 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

Biology of incretins: GLP-1 and GIP

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

Role of bile acid sequestrants in the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

Physiologic and weight-focused treatment strategies for managing type 2 diabetes mellitus: the metformin, glucagon-like peptide-1 receptor agonist, and insulin (MGI) approach

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

Treat-to-target trials: uses, interpretation and review of concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

Starting and advancing insulin for type 2 diabetes: algorithms and individualized methods are both necessary.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

A critique of the 2012 ADA/EASD position statement

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

ADA/EASD position statement of the treatment of type 2 diabetes: Reply to Rodbard HW and Jellinger PS [letter], Scheen AJ [letter] and Ceriello A, Gallo M, Gentile S et al [letter].

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

Bromocriptine mesylate: Food and Drug Administration approved new approach in therapy of non-insulin dependant diabetes mellitus with poor glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2759

21 January 2018

Identifiers

DOI

10.3810/PGM.2014.05.2759

1 reference

31 August 2017

1 reference